Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome.
Intravenous infusions of 250,000 U of lymphocyte-derived or recombinant DNA-derived interleukin-2 (IL-2) were administered to patients with the acquired immunodeficiency syndrome, and sera were obtained for pharmacokinetic studies. A methodology was developed for the determination of serum levels of interleukin-2, which resulted in a coefficient of variation of less than 8% and a sensitivity 32-fold greater than that of the traditional methodology using probit analysis of half-maximal stimulation. In addition to the previously described rapid clearance of IL-2, a later phase of interleukin-2 clearance with a half-life greater than 90 min was observed; bioactive interleukin-2 remained in the circulation for several hours after infusion.
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood* / Q000628:therapy; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007376:Interleukin-2 / Q000008:administration & dosage / Q000302:isolation & purification / Q000502:physiology*; D007700:Kinetics; D008214:Lymphocytes / Q000276:immunology
D004274:DNA, Recombinant; D007376:Interleukin-2